Company: SXTPW
Filing Date: 2025-02-06
Form Type: 424B5
Source: 0001213900-25-010772
Chunk: 7

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-06
Form: 424B5
Chunk 7
---
 chronic fatigue syndrome in the U.S. is at least 3.3 million cases (excluding Long COVID and PTLDS). 9

| 4 | Conclusions                                
 from Company-commissioned market research. |

| 5 | Maximum                                                                                       
 prevalence determined by multiplying the rate of Babesia coinfection in PTLDS patients (52%,  
 from Parveen & Bhanot, Pathogens 2019;8(3):117) by the highest estimate of the cumulative     
 prevalence of PTLDS (1,994,189, from Delong et al. BMC Public Health 2019;19(1):352). Maximum 
 new cases determined by multiplying the number of new Lyme cases per year (476,000, from      
 Krugeler et al (Emerg Infect Dis 2021;27:616-61) by the number of new cases that subsequently 
 become chronic cases (up to 10%, from Delong et al. BMC Public Health 2019;19(1):352) by      
 the proportion of such patients coinfected with Babesia (52%, from Parveen & Bhanot,          
 Pathogens 2019;8(3):117).                                                                     |

| 6 | See                                                                             
 https://www.cdc.gov/lyme/signs-symptoms/chronic-symptoms-and-lyme-disease.html. |

| 7 | Walitt                                   
 et al Nature Communications 2024;15:907. |

| 8 | Lindner                                                                                      
 HH. 2022. Chronic babesiosis caused by B. odocoilei: Diagnosis, pathophysiology & treatment. 
 Presentation at the 2022 ILADS scientific meeting, Orlando Florida.                          |

| 9 | See                                                 
 https://www.cdc.gov/nchs/data/databriefs/db488.pdf. |

<div align='center'>S-2</div>

Separately from the clinical indication, based on estimates from industry experts, there may be somewhere between several hundred and several thousand cases of canine babesiosis each year in the United States, and thousands more globally. Currently, standard of care treatment for babesiosis in dogs is a ten-day course of atovaquone and azithromycin, which costs about $1,350 out of pocket. A treatment course of Tafenoquine mirroring the human prophylactic dose in dogs might cost < $300, offering a compelling alternative to standard of care. The additional